Review





Similar Products

murine luminal b breast cancer cell line eo771  (ATCC)
96
ATCC murine luminal b breast cancer cell line eo771
Intra-tumoral adenosine concentration (Mean ± SEM) in (A) human and (B) murine breast tumors and normal breast tissue quantified by LC-MS. (C) IHC staining: Magnification 200 X, Scale 100 μM and (D, E) H-score (Mean ± SEM) of CD73 and A 2a R in human normal breast tissue (epithelial cells, immune cells) and breast tumors (cancer cells, immune cells). (F) Relative expression of genes in the adenosine signaling axis in <t>EO771</t> and 4T1 murine breast cancer cells compared to GAPDH by qPCR. (G) Frequency of immune cell subtypes (Mean ± SEM) in EO771 tumors by spectral flow cytometry. (H) Frequency of immune cell subtypes (Mean ± SEM) in 4T1 tumors by spectral flow cytometry. (I) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of EO771 tumors. (J) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of 4T1 tumors. (K) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in EO771 tumors quantified using spectral flow cytometry. (L) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in 4T1 tumors quantified using spectral flow cytometry. Tumors were harvested from n=10-12 mice, 25 days post-implantation. (myeloid cells (CD45 + CD11b + TCRβ - ), T cells (CD45 + CD11b - TCRβ + ), B-cells (CD45 + CD11b - CD19 + ), dendritic cells (CD45 + CD11b - CD11c + CD103 + ), NK cell – natural killer cells (CD45 + CD11b - CD11c - NK1.1 + ).
Murine Luminal B Breast Cancer Cell Line Eo771, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/luminal+a+breast+cancers/EO771/bio_rxiv__64898__2026__05__26__727904-47-0-26
Average 96 stars, based on 1 article reviews
murine luminal b breast cancer cell line eo771 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
human luminal a breast cancer cells  (ATCC)
99
ATCC human luminal a breast cancer cells
Intra-tumoral adenosine concentration (Mean ± SEM) in (A) human and (B) murine breast tumors and normal breast tissue quantified by LC-MS. (C) IHC staining: Magnification 200 X, Scale 100 μM and (D, E) H-score (Mean ± SEM) of CD73 and A 2a R in human normal breast tissue (epithelial cells, immune cells) and breast tumors (cancer cells, immune cells). (F) Relative expression of genes in the adenosine signaling axis in <t>EO771</t> and 4T1 murine breast cancer cells compared to GAPDH by qPCR. (G) Frequency of immune cell subtypes (Mean ± SEM) in EO771 tumors by spectral flow cytometry. (H) Frequency of immune cell subtypes (Mean ± SEM) in 4T1 tumors by spectral flow cytometry. (I) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of EO771 tumors. (J) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of 4T1 tumors. (K) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in EO771 tumors quantified using spectral flow cytometry. (L) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in 4T1 tumors quantified using spectral flow cytometry. Tumors were harvested from n=10-12 mice, 25 days post-implantation. (myeloid cells (CD45 + CD11b + TCRβ - ), T cells (CD45 + CD11b - TCRβ + ), B-cells (CD45 + CD11b - CD19 + ), dendritic cells (CD45 + CD11b - CD11c + CD103 + ), NK cell – natural killer cells (CD45 + CD11b - CD11c - NK1.1 + ).
Human Luminal A Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/luminal+a+breast+cancers/MCF7/10__3390_slash_metabo16060349-52-0-7
Average 99 stars, based on 1 article reviews
human luminal a breast cancer cells - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
luminal a t 47d breast cancer cell line  (ATCC)
99
ATCC luminal a t 47d breast cancer cell line
Intra-tumoral adenosine concentration (Mean ± SEM) in (A) human and (B) murine breast tumors and normal breast tissue quantified by LC-MS. (C) IHC staining: Magnification 200 X, Scale 100 μM and (D, E) H-score (Mean ± SEM) of CD73 and A 2a R in human normal breast tissue (epithelial cells, immune cells) and breast tumors (cancer cells, immune cells). (F) Relative expression of genes in the adenosine signaling axis in <t>EO771</t> and 4T1 murine breast cancer cells compared to GAPDH by qPCR. (G) Frequency of immune cell subtypes (Mean ± SEM) in EO771 tumors by spectral flow cytometry. (H) Frequency of immune cell subtypes (Mean ± SEM) in 4T1 tumors by spectral flow cytometry. (I) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of EO771 tumors. (J) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of 4T1 tumors. (K) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in EO771 tumors quantified using spectral flow cytometry. (L) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in 4T1 tumors quantified using spectral flow cytometry. Tumors were harvested from n=10-12 mice, 25 days post-implantation. (myeloid cells (CD45 + CD11b + TCRβ - ), T cells (CD45 + CD11b - TCRβ + ), B-cells (CD45 + CD11b - CD19 + ), dendritic cells (CD45 + CD11b - CD11c + CD103 + ), NK cell – natural killer cells (CD45 + CD11b - CD11c - NK1.1 + ).
Luminal A T 47d Breast Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/luminal+a+breast+cancers/T-47D/pm41940724-410-0-11
Average 99 stars, based on 1 article reviews
luminal a t 47d breast cancer cell line - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
luminal a breast cancer cell line mcf7  (ATCC)
99
ATCC luminal a breast cancer cell line mcf7
Intra-tumoral adenosine concentration (Mean ± SEM) in (A) human and (B) murine breast tumors and normal breast tissue quantified by LC-MS. (C) IHC staining: Magnification 200 X, Scale 100 μM and (D, E) H-score (Mean ± SEM) of CD73 and A 2a R in human normal breast tissue (epithelial cells, immune cells) and breast tumors (cancer cells, immune cells). (F) Relative expression of genes in the adenosine signaling axis in <t>EO771</t> and 4T1 murine breast cancer cells compared to GAPDH by qPCR. (G) Frequency of immune cell subtypes (Mean ± SEM) in EO771 tumors by spectral flow cytometry. (H) Frequency of immune cell subtypes (Mean ± SEM) in 4T1 tumors by spectral flow cytometry. (I) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of EO771 tumors. (J) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of 4T1 tumors. (K) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in EO771 tumors quantified using spectral flow cytometry. (L) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in 4T1 tumors quantified using spectral flow cytometry. Tumors were harvested from n=10-12 mice, 25 days post-implantation. (myeloid cells (CD45 + CD11b + TCRβ - ), T cells (CD45 + CD11b - TCRβ + ), B-cells (CD45 + CD11b - CD19 + ), dendritic cells (CD45 + CD11b - CD11c + CD103 + ), NK cell – natural killer cells (CD45 + CD11b - CD11c - NK1.1 + ).
Luminal A Breast Cancer Cell Line Mcf7, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/luminal+a+breast+cancers/MCF7/pm41904654-138-1-12
Average 99 stars, based on 1 article reviews
luminal a breast cancer cell line mcf7 - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
mcf7 luminal human breast cancer cell lines  (ATCC)
99
ATCC mcf7 luminal human breast cancer cell lines
Intra-tumoral adenosine concentration (Mean ± SEM) in (A) human and (B) murine breast tumors and normal breast tissue quantified by LC-MS. (C) IHC staining: Magnification 200 X, Scale 100 μM and (D, E) H-score (Mean ± SEM) of CD73 and A 2a R in human normal breast tissue (epithelial cells, immune cells) and breast tumors (cancer cells, immune cells). (F) Relative expression of genes in the adenosine signaling axis in <t>EO771</t> and 4T1 murine breast cancer cells compared to GAPDH by qPCR. (G) Frequency of immune cell subtypes (Mean ± SEM) in EO771 tumors by spectral flow cytometry. (H) Frequency of immune cell subtypes (Mean ± SEM) in 4T1 tumors by spectral flow cytometry. (I) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of EO771 tumors. (J) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of 4T1 tumors. (K) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in EO771 tumors quantified using spectral flow cytometry. (L) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in 4T1 tumors quantified using spectral flow cytometry. Tumors were harvested from n=10-12 mice, 25 days post-implantation. (myeloid cells (CD45 + CD11b + TCRβ - ), T cells (CD45 + CD11b - TCRβ + ), B-cells (CD45 + CD11b - CD19 + ), dendritic cells (CD45 + CD11b - CD11c + CD103 + ), NK cell – natural killer cells (CD45 + CD11b - CD11c - NK1.1 + ).
Mcf7 Luminal Human Breast Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/luminal+a+breast+cancers/MCF7/pm41895619-83-3-17
Average 99 stars, based on 1 article reviews
mcf7 luminal human breast cancer cell lines - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
luminal a breast cancer cell lines mcf 7  (ATCC)
99
ATCC luminal a breast cancer cell lines mcf 7
Intra-tumoral adenosine concentration (Mean ± SEM) in (A) human and (B) murine breast tumors and normal breast tissue quantified by LC-MS. (C) IHC staining: Magnification 200 X, Scale 100 μM and (D, E) H-score (Mean ± SEM) of CD73 and A 2a R in human normal breast tissue (epithelial cells, immune cells) and breast tumors (cancer cells, immune cells). (F) Relative expression of genes in the adenosine signaling axis in <t>EO771</t> and 4T1 murine breast cancer cells compared to GAPDH by qPCR. (G) Frequency of immune cell subtypes (Mean ± SEM) in EO771 tumors by spectral flow cytometry. (H) Frequency of immune cell subtypes (Mean ± SEM) in 4T1 tumors by spectral flow cytometry. (I) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of EO771 tumors. (J) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of 4T1 tumors. (K) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in EO771 tumors quantified using spectral flow cytometry. (L) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in 4T1 tumors quantified using spectral flow cytometry. Tumors were harvested from n=10-12 mice, 25 days post-implantation. (myeloid cells (CD45 + CD11b + TCRβ - ), T cells (CD45 + CD11b - TCRβ + ), B-cells (CD45 + CD11b - CD19 + ), dendritic cells (CD45 + CD11b - CD11c + CD103 + ), NK cell – natural killer cells (CD45 + CD11b - CD11c - NK1.1 + ).
Luminal A Breast Cancer Cell Lines Mcf 7, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/luminal+a+breast+cancers/MCF7/pm41713536-215-10-25
Average 99 stars, based on 1 article reviews
luminal a breast cancer cell lines mcf 7 - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
luminal breast cancer  (ATCC)
97
ATCC luminal breast cancer
Intra-tumoral adenosine concentration (Mean ± SEM) in (A) human and (B) murine breast tumors and normal breast tissue quantified by LC-MS. (C) IHC staining: Magnification 200 X, Scale 100 μM and (D, E) H-score (Mean ± SEM) of CD73 and A 2a R in human normal breast tissue (epithelial cells, immune cells) and breast tumors (cancer cells, immune cells). (F) Relative expression of genes in the adenosine signaling axis in <t>EO771</t> and 4T1 murine breast cancer cells compared to GAPDH by qPCR. (G) Frequency of immune cell subtypes (Mean ± SEM) in EO771 tumors by spectral flow cytometry. (H) Frequency of immune cell subtypes (Mean ± SEM) in 4T1 tumors by spectral flow cytometry. (I) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of EO771 tumors. (J) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of 4T1 tumors. (K) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in EO771 tumors quantified using spectral flow cytometry. (L) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in 4T1 tumors quantified using spectral flow cytometry. Tumors were harvested from n=10-12 mice, 25 days post-implantation. (myeloid cells (CD45 + CD11b + TCRβ - ), T cells (CD45 + CD11b - TCRβ + ), B-cells (CD45 + CD11b - CD19 + ), dendritic cells (CD45 + CD11b - CD11c + CD103 + ), NK cell – natural killer cells (CD45 + CD11b - CD11c - NK1.1 + ).
Luminal Breast Cancer, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/luminal+a+breast+cancers/ZR-75-1/pmc12817083-38-12-45
Average 97 stars, based on 1 article reviews
luminal breast cancer - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
luminal breast cancer mcf 7 cell line  (ATCC)
99
ATCC luminal breast cancer mcf 7 cell line
Intra-tumoral adenosine concentration (Mean ± SEM) in (A) human and (B) murine breast tumors and normal breast tissue quantified by LC-MS. (C) IHC staining: Magnification 200 X, Scale 100 μM and (D, E) H-score (Mean ± SEM) of CD73 and A 2a R in human normal breast tissue (epithelial cells, immune cells) and breast tumors (cancer cells, immune cells). (F) Relative expression of genes in the adenosine signaling axis in <t>EO771</t> and 4T1 murine breast cancer cells compared to GAPDH by qPCR. (G) Frequency of immune cell subtypes (Mean ± SEM) in EO771 tumors by spectral flow cytometry. (H) Frequency of immune cell subtypes (Mean ± SEM) in 4T1 tumors by spectral flow cytometry. (I) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of EO771 tumors. (J) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of 4T1 tumors. (K) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in EO771 tumors quantified using spectral flow cytometry. (L) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in 4T1 tumors quantified using spectral flow cytometry. Tumors were harvested from n=10-12 mice, 25 days post-implantation. (myeloid cells (CD45 + CD11b + TCRβ - ), T cells (CD45 + CD11b - TCRβ + ), B-cells (CD45 + CD11b - CD19 + ), dendritic cells (CD45 + CD11b - CD11c + CD103 + ), NK cell – natural killer cells (CD45 + CD11b - CD11c - NK1.1 + ).
Luminal Breast Cancer Mcf 7 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/luminal+a+breast+cancers/MCF7/pm41540620-160-0-6
Average 99 stars, based on 1 article reviews
luminal breast cancer mcf 7 cell line - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

Image Search Results


Intra-tumoral adenosine concentration (Mean ± SEM) in (A) human and (B) murine breast tumors and normal breast tissue quantified by LC-MS. (C) IHC staining: Magnification 200 X, Scale 100 μM and (D, E) H-score (Mean ± SEM) of CD73 and A 2a R in human normal breast tissue (epithelial cells, immune cells) and breast tumors (cancer cells, immune cells). (F) Relative expression of genes in the adenosine signaling axis in EO771 and 4T1 murine breast cancer cells compared to GAPDH by qPCR. (G) Frequency of immune cell subtypes (Mean ± SEM) in EO771 tumors by spectral flow cytometry. (H) Frequency of immune cell subtypes (Mean ± SEM) in 4T1 tumors by spectral flow cytometry. (I) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of EO771 tumors. (J) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of 4T1 tumors. (K) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in EO771 tumors quantified using spectral flow cytometry. (L) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in 4T1 tumors quantified using spectral flow cytometry. Tumors were harvested from n=10-12 mice, 25 days post-implantation. (myeloid cells (CD45 + CD11b + TCRβ - ), T cells (CD45 + CD11b - TCRβ + ), B-cells (CD45 + CD11b - CD19 + ), dendritic cells (CD45 + CD11b - CD11c + CD103 + ), NK cell – natural killer cells (CD45 + CD11b - CD11c - NK1.1 + ).

Journal: bioRxiv

Article Title: Targeting CD73-A 2a R-Mediated Adenosine Signaling at the Tumor-Immune Interface Overcomes Radioresistance

doi: 10.64898/2026.05.26.727904

Figure Lengend Snippet: Intra-tumoral adenosine concentration (Mean ± SEM) in (A) human and (B) murine breast tumors and normal breast tissue quantified by LC-MS. (C) IHC staining: Magnification 200 X, Scale 100 μM and (D, E) H-score (Mean ± SEM) of CD73 and A 2a R in human normal breast tissue (epithelial cells, immune cells) and breast tumors (cancer cells, immune cells). (F) Relative expression of genes in the adenosine signaling axis in EO771 and 4T1 murine breast cancer cells compared to GAPDH by qPCR. (G) Frequency of immune cell subtypes (Mean ± SEM) in EO771 tumors by spectral flow cytometry. (H) Frequency of immune cell subtypes (Mean ± SEM) in 4T1 tumors by spectral flow cytometry. (I) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of EO771 tumors. (J) Abundance of adenosine signaling proteins (Mean ± SEM). in CD45 - compartment of 4T1 tumors. (K) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in EO771 tumors quantified using spectral flow cytometry. (L) Expression of adenosine signaling proteins on CD45 + immune cells (Mean ± SEM) in 4T1 tumors quantified using spectral flow cytometry. Tumors were harvested from n=10-12 mice, 25 days post-implantation. (myeloid cells (CD45 + CD11b + TCRβ - ), T cells (CD45 + CD11b - TCRβ + ), B-cells (CD45 + CD11b - CD19 + ), dendritic cells (CD45 + CD11b - CD11c + CD103 + ), NK cell – natural killer cells (CD45 + CD11b - CD11c - NK1.1 + ).

Article Snippet: Murine luminal B breast cancer cell line EO771 (ERα-, ERβ+, PR+, HER2+) and triple negative breast cancer cell line 4T1 (ER-, PR-, HER2-) was procured from ATCC.

Techniques: Concentration Assay, Liquid Chromatography with Mass Spectroscopy, Immunohistochemistry, Expressing, Flow Cytometry

(A) Fold change in intra-tumoral adenosine concentrations in irradiated (8Gy x 1) EO771 tumors 12-, 24-, 48-, and 72-hours after treatment calculated with respect to adenosine concentration in unirradiated tumors. Abundance (Mean ± SEM) of (B) myeloid cells (CD45 + CD11b + ) and (C) T lymphocytes (CD45 + TCRb + ) in EO771 tumors on days 1,3,5,11 after irradiation (8Gy x 3) compared to unirradiated controls. Data are representative of two separate experiments, n=10-12 mice/group. (***) p<0.001, (****) p<0.0005. Log2 fold changes in gene expression in irradiated cells versus the corresponding unirradiated cells on day 1 (D1), 3 (D3), 5 (D5) in (D) CD45 + CD11b + cells (E) CD45 + TCRb + cells (F) CD45 - cells sorted from intra-tumoral cell suspensions (n=3 mice/group). Log2 fold changes in gene expression of adenosine signaling genes in irradiated cells versus the corresponding unirradiated cells on day 1, 3, 5 in (G) CD45 + CD11b + cells (H) CD45 + TCRb + cells (I) CD45 - cells sorted from intra-tumoral cell suspensions (n=3 mice/group).

Journal: bioRxiv

Article Title: Targeting CD73-A 2a R-Mediated Adenosine Signaling at the Tumor-Immune Interface Overcomes Radioresistance

doi: 10.64898/2026.05.26.727904

Figure Lengend Snippet: (A) Fold change in intra-tumoral adenosine concentrations in irradiated (8Gy x 1) EO771 tumors 12-, 24-, 48-, and 72-hours after treatment calculated with respect to adenosine concentration in unirradiated tumors. Abundance (Mean ± SEM) of (B) myeloid cells (CD45 + CD11b + ) and (C) T lymphocytes (CD45 + TCRb + ) in EO771 tumors on days 1,3,5,11 after irradiation (8Gy x 3) compared to unirradiated controls. Data are representative of two separate experiments, n=10-12 mice/group. (***) p<0.001, (****) p<0.0005. Log2 fold changes in gene expression in irradiated cells versus the corresponding unirradiated cells on day 1 (D1), 3 (D3), 5 (D5) in (D) CD45 + CD11b + cells (E) CD45 + TCRb + cells (F) CD45 - cells sorted from intra-tumoral cell suspensions (n=3 mice/group). Log2 fold changes in gene expression of adenosine signaling genes in irradiated cells versus the corresponding unirradiated cells on day 1, 3, 5 in (G) CD45 + CD11b + cells (H) CD45 + TCRb + cells (I) CD45 - cells sorted from intra-tumoral cell suspensions (n=3 mice/group).

Article Snippet: Murine luminal B breast cancer cell line EO771 (ERα-, ERβ+, PR+, HER2+) and triple negative breast cancer cell line 4T1 (ER-, PR-, HER2-) was procured from ATCC.

Techniques: Irradiation, Concentration Assay, Gene Expression

(A) Adenosine concentration (Mean ± SEM) measured in cell-free supernatant from WT (EO771.lmb), ENPP1 -/- , CD73 -/- , ENPP1 -/- CD73 -/- cells grown in vitro, 18 hours after irradiation (8 Gy x 1), compared to untreated controls. (B) Tumor volume (Mean ± SEM) from WT mice bearing WT EO771, CD73 -/- EO771, or Enpp1 -/- EO771 tumors. (C, D) Tumor volume (Mean ± SEM) and survival of WT mice bearing WT EO771, CD73 -/- EO771, or Enpp1 -/- EO771 tumors irradiated (8Gy x 3) on days 13, 14, 15 post-implantation. (E, F) Tumor volume (Mean ± SEM) of orthotopic EO771 tumors implanted in wildtype (WT, C57BL6/J), CD73 -/- and A 2a R -/- A 2b R -/- mice. (G) Intra-tumoral adenosine concentration (Mean ± SEM) in paired normal murine breast tissue and EO771 tumors implanted in WT, CD73 -/- and A 2a R -/- A 2b R -/- mice. (H) Tumor volumes (Mean ± SEM) from WT (C57BL6/J), CD73 -/- , A 2a R -/- A 2b R -/- mice implanted with EO771 cells irradiated (8 Gy x 3) on days 13, 14, 15 post-implantation. Tumor volumes (Mean ± SEM) from (I) untreated and (J) radiation-treated (8Gy x 3) tumors from LysM Cre , A 2a R fl/fl , LysM Cre A 2a R fl/- , LysM Cre A 2a R fl/fl mice implanted with EO771 cells. Data are representative of two separate experiments, n=10-12 mice/group (*) p<0.05 (**), p<0.01(***), p<0.001, (****)p<0.0005.

Journal: bioRxiv

Article Title: Targeting CD73-A 2a R-Mediated Adenosine Signaling at the Tumor-Immune Interface Overcomes Radioresistance

doi: 10.64898/2026.05.26.727904

Figure Lengend Snippet: (A) Adenosine concentration (Mean ± SEM) measured in cell-free supernatant from WT (EO771.lmb), ENPP1 -/- , CD73 -/- , ENPP1 -/- CD73 -/- cells grown in vitro, 18 hours after irradiation (8 Gy x 1), compared to untreated controls. (B) Tumor volume (Mean ± SEM) from WT mice bearing WT EO771, CD73 -/- EO771, or Enpp1 -/- EO771 tumors. (C, D) Tumor volume (Mean ± SEM) and survival of WT mice bearing WT EO771, CD73 -/- EO771, or Enpp1 -/- EO771 tumors irradiated (8Gy x 3) on days 13, 14, 15 post-implantation. (E, F) Tumor volume (Mean ± SEM) of orthotopic EO771 tumors implanted in wildtype (WT, C57BL6/J), CD73 -/- and A 2a R -/- A 2b R -/- mice. (G) Intra-tumoral adenosine concentration (Mean ± SEM) in paired normal murine breast tissue and EO771 tumors implanted in WT, CD73 -/- and A 2a R -/- A 2b R -/- mice. (H) Tumor volumes (Mean ± SEM) from WT (C57BL6/J), CD73 -/- , A 2a R -/- A 2b R -/- mice implanted with EO771 cells irradiated (8 Gy x 3) on days 13, 14, 15 post-implantation. Tumor volumes (Mean ± SEM) from (I) untreated and (J) radiation-treated (8Gy x 3) tumors from LysM Cre , A 2a R fl/fl , LysM Cre A 2a R fl/- , LysM Cre A 2a R fl/fl mice implanted with EO771 cells. Data are representative of two separate experiments, n=10-12 mice/group (*) p<0.05 (**), p<0.01(***), p<0.001, (****)p<0.0005.

Article Snippet: Murine luminal B breast cancer cell line EO771 (ERα-, ERβ+, PR+, HER2+) and triple negative breast cancer cell line 4T1 (ER-, PR-, HER2-) was procured from ATCC.

Techniques: Concentration Assay, In Vitro, Irradiation

(A) Schematic summary of treatment schedule for EO771 or 4T1 orthotopic breast cancer model. (B) Tumor volume measurements (Mean ± SEM) beginning 8 days after EO771 implantation (n=8-10 mice/group). AB680 (quemliclustat, CD73 inhibitor), AB928 (etrumadenant, A 2a R/A 2b R antagonist), αPD1 (zimberelimab, anti-PD-1 antibody), isotype control (IgG2 antibody), tumor irradiation (RT, 8 Gy x 3; 12-, 13-, 14- days after implantation). (C) Tumor volumes from days 8-42 of irradiated mice treated in combination with isotype control, anti-PD-1, AB928 and AB680, AB928 and AB680 and anti-PD-1. (D) Spider plots of tumors from mice belonging to all treatment groups implanted with EO771 cells. (E) Slopes (Mean ± SEM) during tumor rebound period (days 32-42) from growth curves of mice belonging to irradiation and anti-PD-1, irradiation and AB680 and AB928, irradiation and AB680 and AB928 and anti-PD-1 treatment groups. (F) Tumor volume measurements (Mean ± SEM) beginning 8 days after 4T1 implantation. Data are representative of two separate experiments, n=8-10 mice/group (*) p<0.05 (**), p<0.01, (****) p<0.0005.

Journal: bioRxiv

Article Title: Targeting CD73-A 2a R-Mediated Adenosine Signaling at the Tumor-Immune Interface Overcomes Radioresistance

doi: 10.64898/2026.05.26.727904

Figure Lengend Snippet: (A) Schematic summary of treatment schedule for EO771 or 4T1 orthotopic breast cancer model. (B) Tumor volume measurements (Mean ± SEM) beginning 8 days after EO771 implantation (n=8-10 mice/group). AB680 (quemliclustat, CD73 inhibitor), AB928 (etrumadenant, A 2a R/A 2b R antagonist), αPD1 (zimberelimab, anti-PD-1 antibody), isotype control (IgG2 antibody), tumor irradiation (RT, 8 Gy x 3; 12-, 13-, 14- days after implantation). (C) Tumor volumes from days 8-42 of irradiated mice treated in combination with isotype control, anti-PD-1, AB928 and AB680, AB928 and AB680 and anti-PD-1. (D) Spider plots of tumors from mice belonging to all treatment groups implanted with EO771 cells. (E) Slopes (Mean ± SEM) during tumor rebound period (days 32-42) from growth curves of mice belonging to irradiation and anti-PD-1, irradiation and AB680 and AB928, irradiation and AB680 and AB928 and anti-PD-1 treatment groups. (F) Tumor volume measurements (Mean ± SEM) beginning 8 days after 4T1 implantation. Data are representative of two separate experiments, n=8-10 mice/group (*) p<0.05 (**), p<0.01, (****) p<0.0005.

Article Snippet: Murine luminal B breast cancer cell line EO771 (ERα-, ERβ+, PR+, HER2+) and triple negative breast cancer cell line 4T1 (ER-, PR-, HER2-) was procured from ATCC.

Techniques: Control, Irradiation